surmount-1 trial tirzepatide weight loss results GLP-1 drugs produce real loss. Around 25% of it isn't fat. In the trial, roughly a quarter of all weight lost on was lean tissue. That is 5.6 kg TrimRX | Tirzepatide Weight Loss

Juan Chavez, MD and Dr

Tirzepatide is a dual-action GLP-1/GIP receptor agonist that targets two hormone pathways involved in appetite regulation, gastric emptying, and blood sugar control

Tirzepatide slowed the rate of decline in estimated glomerular filtration rate (eGFR) and reduced urinary albumin-to-creatinine ratio (UACR) compared with insulin glargine (UACR remained stable with tirzepatide but increased with insulin glargine), including in participants already receiving an angiotensin-converting enzyme inhibitor, angiotensin receptor blocker or sodium-glucose cotransporter 2 inhibitor (SGLT2i)

Each pen delivers a precise, fixed dose, removing the need for manual drawing up of medication

A few patterns worth noting: 10 mg/mL is the industry standard because every milligram corresponds to exactly 10 units, making mental math trivial

To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded GLP-1smedications containing the same active ingredients as blockbuster weight-loss drugs but sold at a much lower price